medigraphic.com
ISSN 1405-1710 (Print)

2007, Number 3

<< Back Next >>

Rev Cent Dermatol Pascua 2007; 16 (3)

Dermatitis herpetiformis

Pérez CS, Peña OJ, Ramos GA, Pérez MCA

Language: Spanish
References: 18
Page: 137-142
PDF size: 163.43 Kb.


ABSTRACT

This review discusses the epidemiology, pathogenesis, diagnosis and current therapeutic options for dermatitis herpetiformis (DH). Is a pruritic and blistering disease, related to gluten-sensitive enteropathy usually appears between the ages of 30 and 50 years and is more common among men than women. The course of DH is chronic with remissions and exacerbations of lesion in typical regions (knees, elbows, buttocks). The standard for diagnosis of DH is direct immunofluorescence. DH is often treated with suppressive medications such as dapsone, in conjunction with a gluten-free diet.


REFERENCES

  1. Nicolas ME, Krause P, Gibson L, Murray J. Dermatitis herpetiformis. International Journal of Dermatology 2003; 42: 588.

  2. Oxentenko A, Murray J. Celiac disease and dermatitis herpetiformis: the spectrum of gluten-sensitive enteropathy. International Journal of Dermatology 2003; 42: 585.

  3. Reunala T. Incidence of familial dermatitis herpetiformis. Br J Dermatol 1996; 134: 394.

  4. Sardy M, Karpati S, Merkl B. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002; 195: 747.

  5. Arenas R. Atlas de dermatología. México; Interamericana. McGraw-Hill, 2005: 149-151.

  6. Wolf K, Johnson RA. Atlas en color y sinopsis de dermatología clínica. México; Interamericana, McGraw-Hill, 2005: 111-115.

  7. Pierce DK, Purcell SM, Spielvogel RL. Purpuric papules and vesicles of the palms in dermatitis herpetiformis. J Am Acad Dermatol 1987; 16: 1274.

  8. Christensen OB, Hindsen M, Svensson A. Natural history of dermatitis herpetiformis in southern Sweden. Dermatologica 1986; 173: 271.

  9. Kaukinen K, Maki M, Partanen J. Celiac disease without villous atrophy: revision of criteria called for. Dig Dis Sci 2001; 46: 879.

  10. Zone JJ, Meyer LJ, Petersen MJ. Deposition of grandular IgA relative clinical lesions in dermatitis herpetiformis. Arch Dermatol 1996; 132: 912.

  11. Caproni M, Cardinali C, Renzi D. Tissue transglutaminase antibody assessment in dermatitis herpetiformis. Br J Dermatol 2001; 144: 196.

  12. Desai AM, Krishnan R, Hsu S. Medical pearl: Using tissue transglutaminase antibodies to diagnose dermatitis herpetiformis. J Am Acad Dermatol 2005; 53: 867.

  13. Prussick R, Ali MA, Rosenthal D, Guyatt G. The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Arch Dermatol 1992; 128: 210.

  14. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001; 45: 420.

  15. García G, Mohr Y, Dancziger E. Eficacia de la colchicina en el tratamiento de la dermatitis herpetiforme. Act Terap Dermatol 2006; 29: 242-252.

  16. Mutasim DF. Management of autoimmune bullous diseases: pharmacology and therapeutics. Am Acad Dermatol 2004; 51: 859.

  17. Reunala T, Collin P. Diseases associated with dermatitis herpetiformis. Br J Dermatol 1997; 136: 315.

  18. Hervonen K, Vornanen M, Kautiainen H, Collin P, Reunala T. Lymphoma in patients with dermatitis herpetiformis and their first-degree relatives. British Journal of Dermatology 2005; 152: 82.




2020     |     www.medigraphic.com